Inhibitor of nuclear factor kappa-B kinase subunit epsilon–TANK-binding kinase 1 complex (IKKε–TBK1) (IKKε–TBK1)

The Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) and TANK-binding kinase 1 (TBK1) form a complex of non-canonical IκB kinases that are essential mediators of the innate immune response. These kinases share approximately 65% sequence identity and are primarily responsible for phosphorylating Interferon Regulatory Factors 3 and 7 (IRF3/7), which triggers the production of Type I interferons in response to viral or bacterial stimuli (UniProt Q9UHD2, Q14164). In addition to their role in immunity, the IKKε–TBK1 complex is frequently dysregulated in various malignancies, where it promotes cell survival and "non-oncogene addiction," particularly in KRAS-mutant cancers, by activating the NF-κB and Akt signaling pathways (Nature, PMID: 19812548). The complex also plays a significant role in regulating autophagy and metabolic processes, with its inhibition showing potential in treating obesity and type 2 diabetes (Nature Medicine, PMID: 23434247). Mutations in the TBK1 component are specifically linked to neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), reflecting its importance in protein clearance (PMID: 25970234). Pharmacological targeting of this complex typically involves small-molecule ATP-competitive inhibitors, though therapeutic development must balance efficacy with the risk of impaired antiviral immunity.

Other names

IKBKE–TBK1 complexNon-canonical IKK complexNAK–IKKε complexIKK-epsilon–TBK1 complexIKBKETBK1NAKT2KIKK-i

ATP-competitive inhibition of the kinase domains of both IKKε and TBK1, preventing the phosphorylation of downstream transcription factors like IRF3 and IRF7, thereby blocking Type I interferon production and pro-survival NF-κB signaling.